The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE substudy

Albert H. Hauber; EP Havranek; TA Simon; G L'italien; A Smitten; Brett Hauber; R Chen; P Lapuerta

The relationship between health perception and utility in heart failure patients in a clinical trial

Results from an OVERTURE substudy

Havranek, EP., Simon, TA., L'Italien, G., Smitten, A., Hauber, AB., Chen, R., & Lapuerta, P. (2004). The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE substudy. Journal of Cardiac Failure, 10(4), 339-343. https://doi.org/10.1016/j.cardfail.2003.11.002

Copy citation

Abstract

Background: Cost-effectiveness analyses should be based on incremental years of life gained adjusted with a health status measure known as a utility. Measuring utilities for all subjects in a large-scale randomized trial, however, would be prohibitively cumbersome. We therefore sought to estimate utilities for all subjects from results obtained in a subset of patients.

Methods and Results: We studied a subset of patients enrolled in a randomized trial of omapatrilat for the treatment of heart failure. Survey instruments (a time trade-off questionnaire, a visual analog scale [VAS] score of overall health perception, and the Duke Activity Status Index [DASI]) were administered to patients by mail and by telephone interviews. There was a significant (P <.0001) relationship between VAS score and utility described by the power function u = 1-(1-v)q, where q = 2.17 (95% CI 1.76 to 2.58). There was a significant positive correlation (r = .17, P <.04) between the DASI and utility, and a significant negative correlation (r = -.26, P <.001) between utility and New York Heart Association functional class.

Conclusion: There is a significant relationship between the relatively easily obtainable health perception score by VAS with the more complex utility by time tradeoff for a subset of patients in a multicenter randomized clinical trial. This relationship may be helpful in examining the cost-effectiveness of new treatments for heart failure.